← All Kalvista Pharmaceuticals, INC filings

Kalvista Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KALV
Kalvista Pharmaceuticals, INC
10-KT/A: KalVista Files 10-KT/A Amendment for Transition Period
KalVista Pharmaceuticals files an amendment to its transition report to include required governance and compensation disclosures ahead of its pending merger.
NASDAQ
KALV
Kalvista Pharmaceuticals, INC
10-KT: KalVista Launches Oral HAE Therapy EKTERLY, Boosts Capital
KalVista Pharmaceuticals reports its first product revenue following FDA approval and global authorizations for EKTERLY, an oral on-demand therapy for HAE, while securing significant financing.
NASDAQ
KALV
Kalvista Pharmaceuticals, INC
10-K: KalVista Pharmaceuticals Secures Landmark FDA Approval for Oral HAE Therapy EKTERLY, Bolstering Global Commercialization Efforts
KalVista Pharmaceuticals, Inc. announced the landmark U.S. FDA approval of EKTERLY (sebetralstat), the first and only oral, on-demand therapy for hereditary angioedema (HAE) in patients aged 12 and older, alongside strategic global commercialization partnerships and a significant royalty financing deal.
NASDAQ
KALV
Kalvista Pharmaceuticals, INC
10-K: KalVista Pharmaceuticals Files NDA for Oral HAE Treatment, Eyes Global Expansion
KalVista Pharmaceuticals has submitted a New Drug Application to the FDA for sebetralstat, a potential first-in-class oral on-demand therapy for hereditary angioedema, with plans for global regulatory submissions.